世界のRAS作用剤市場予測 2023年-2029年

【英語タイトル】Global RAS-acting Agents Market Growth 2023-2029

・商品コード：LP23DC00837
・発行会社（調査会社）：LP Information
・発行日：2023年11月（※2025年版があります。お問い合わせください。）
・ページ数：105
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥541,680	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥812,520	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,083,360	見積依頼/購入/質問フォーム

※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）

❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界のRAS作用剤市場」は、過去の販売実績から2022年の世界のRAS作用剤の総販売量を検討し、2023年から2029年の予測されるRAS作用剤の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別のRAS作用剤の市場規模を掲載し、XXX百万米ドル規模の世界のRAS作用剤市場の詳細な分析を提供します。本インサイトレポートは、世界のRAS作用剤業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界のRAS作用剤市場における各社の独自のポジションをより深く理解するために、RAS作用剤製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界のRAS作用剤市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。RAS作用剤の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。RAS作用剤の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。RAS作用剤のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

RAS作用剤の世界主要メーカーとしては、Novartis AG、 Pfizer, Inc.、 AstraZeneca plc、 Merck & Co., Inc.、 Sanofi S.A.、 Bristol-Myers Squibb Company、 Daiichi Sankyo Company, Limited、 Takeda Pharmaceutical Company Limited、 Boehringer Ingelheim GmbH、 Johnson & Johnsonなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別のRAS作用剤市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査ではRAS作用剤市場をセグメンテーションし、種類別 (ACE阻害薬、アンジオテンシンII受容体拮抗薬（ARB）、レニン阻害薬、アルドステロン拮抗薬、その他（利尿薬）)、用途別 (病院薬局、小売薬局、オンライン薬局)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：ACE阻害薬、アンジオテンシンII受容体拮抗薬（ARB）、レニン阻害薬、アルドステロン拮抗薬、その他（利尿薬）

・用途別区分：病院薬局、小売薬局、オンライン薬局

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界のRAS作用剤市場の10年間の市場状況・展望は？
・世界および地域別に見たRAS作用剤市場成長の要因は何か？
・RAS作用剤の市場機会はエンドマーケットの規模によってどのように変化するのか？
・RAS作用剤のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：RAS作用剤の年間販売量2018-2029、地域別現状・将来分析
・RAS作用剤の種類別セグメント：ACE阻害薬、アンジオテンシンII受容体拮抗薬（ARB）、レニン阻害薬、アルドステロン拮抗薬、その他（利尿薬）
・RAS作用剤の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・RAS作用剤の用途別セグメント：病院薬局、小売薬局、オンライン薬局
・RAS作用剤の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界のRAS作用剤市場
・企業別のグローバルRAS作用剤市場データ：2018-2023年の年間販売量、市場シェア
・企業別のRAS作用剤の年間売上：2018-2023年の売上、市場シェア
・企業別のRAS作用剤販売価格
・主要企業のRAS作用剤生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

RAS作用剤の地域別レビュー
・地域別のRAS作用剤市場規模2018-2023：年間販売量、売上
・主要国別のRAS作用剤市場規模2018-2023：年間販売量、売上
・南北アメリカのRAS作用剤販売の成長
・アジア太平洋のRAS作用剤販売の成長
・ヨーロッパのRAS作用剤販売の成長
・中東・アフリカのRAS作用剤販売の成長

南北アメリカ市場
・南北アメリカの国別のRAS作用剤販売量、売上（2018-2023）
・南北アメリカのRAS作用剤の種類別販売量
・南北アメリカのRAS作用剤の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別のRAS作用剤販売量、売上（2018-2023）
・アジア太平洋のRAS作用剤の種類別販売量
・アジア太平洋のRAS作用剤の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別のRAS作用剤販売量、売上（2018-2023）
・ヨーロッパのRAS作用剤の種類別販売量
・ヨーロッパのRAS作用剤の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別のRAS作用剤販売量、売上（2018-2023）
・中東・アフリカのRAS作用剤の種類別販売量
・中東・アフリカのRAS作用剤の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・RAS作用剤の製造コスト構造分析
・RAS作用剤の製造プロセス分析
・RAS作用剤の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・RAS作用剤の主要なグローバル販売業者
・RAS作用剤の主要なグローバル顧客

地域別のRAS作用剤市場予測レビュー
・地域別のRAS作用剤市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・RAS作用剤の種類別市場規模予測
・RAS作用剤の用途別市場規模予測

主要企業分析
Novartis AG、 Pfizer, Inc.、 AstraZeneca plc、 Merck & Co., Inc.、 Sanofi S.A.、 Bristol-Myers Squibb Company、 Daiichi Sankyo Company, Limited、 Takeda Pharmaceutical Company Limited、 Boehringer Ingelheim GmbH、 Johnson & Johnson
・企業情報
・RAS作用剤製品
・RAS作用剤販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global RAS-acting Agents market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for RAS-acting Agents is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for RAS-acting Agents is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for RAS-acting Agents is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key RAS-acting Agents players cover Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited and Boehringer Ingelheim GmbH, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)’ newest research report, the “RAS-acting Agents Industry Forecast” looks at past sales and reviews total world RAS-acting Agents sales in 2022, providing a comprehensive analysis by region and market sector of projected RAS-acting Agents sales for 2023 through 2029. With RAS-acting Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RAS-acting Agents industry.
This Insight Report provides a comprehensive analysis of the global RAS-acting Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RAS-acting Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RAS-acting Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RAS-acting Agents and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RAS-acting Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of RAS-acting Agents market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
ACE Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Renin Inhibitors
Aldosterone Antagonists
Others (diuretics)
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Novartis AG
Pfizer, Inc.
AstraZeneca plc
Merck & Co., Inc.
Sanofi S.A.
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Takeda Pharmaceutical Company Limited
Boehringer Ingelheim GmbH
Johnson & Johnson
Key Questions Addressed in this Report
What is the 10-year outlook for the global RAS-acting Agents market?
What factors are driving RAS-acting Agents market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do RAS-acting Agents market opportunities vary by end market size?
How does RAS-acting Agents break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global RAS-acting Agents Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for RAS-acting Agents by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for RAS-acting Agents by Country/Region, 2018, 2022 & 2029
2.2 RAS-acting Agents Segment by Type
2.2.1 ACE Inhibitors
2.2.2 Angiotensin II Receptor Blockers (ARBs)
2.2.3 Renin Inhibitors
2.2.4 Aldosterone Antagonists
2.2.5 Others (diuretics)
2.3 RAS-acting Agents Sales by Type
2.3.1 Global RAS-acting Agents Sales Market Share by Type (2018-2023)
2.3.2 Global RAS-acting Agents Revenue and Market Share by Type (2018-2023)
2.3.3 Global RAS-acting Agents Sale Price by Type (2018-2023)
2.4 RAS-acting Agents Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 RAS-acting Agents Sales by Application
2.5.1 Global RAS-acting Agents Sale Market Share by Application (2018-2023)
2.5.2 Global RAS-acting Agents Revenue and Market Share by Application (2018-2023)
2.5.3 Global RAS-acting Agents Sale Price by Application (2018-2023)
3 Global RAS-acting Agents by Company
3.1 Global RAS-acting Agents Breakdown Data by Company
3.1.1 Global RAS-acting Agents Annual Sales by Company (2018-2023)
3.1.2 Global RAS-acting Agents Sales Market Share by Company (2018-2023)
3.2 Global RAS-acting Agents Annual Revenue by Company (2018-2023)
3.2.1 Global RAS-acting Agents Revenue by Company (2018-2023)
3.2.2 Global RAS-acting Agents Revenue Market Share by Company (2018-2023)
3.3 Global RAS-acting Agents Sale Price by Company
3.4 Key Manufacturers RAS-acting Agents Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers RAS-acting Agents Product Location Distribution
3.4.2 Players RAS-acting Agents Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for RAS-acting Agents by Geographic Region
4.1 World Historic RAS-acting Agents Market Size by Geographic Region (2018-2023)
4.1.1 Global RAS-acting Agents Annual Sales by Geographic Region (2018-2023)
4.1.2 Global RAS-acting Agents Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic RAS-acting Agents Market Size by Country/Region (2018-2023)
4.2.1 Global RAS-acting Agents Annual Sales by Country/Region (2018-2023)
4.2.2 Global RAS-acting Agents Annual Revenue by Country/Region (2018-2023)
4.3 Americas RAS-acting Agents Sales Growth
4.4 APAC RAS-acting Agents Sales Growth
4.5 Europe RAS-acting Agents Sales Growth
4.6 Middle East & Africa RAS-acting Agents Sales Growth
5 Americas
5.1 Americas RAS-acting Agents Sales by Country
5.1.1 Americas RAS-acting Agents Sales by Country (2018-2023)
5.1.2 Americas RAS-acting Agents Revenue by Country (2018-2023)
5.2 Americas RAS-acting Agents Sales by Type
5.3 Americas RAS-acting Agents Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RAS-acting Agents Sales by Region
6.1.1 APAC RAS-acting Agents Sales by Region (2018-2023)
6.1.2 APAC RAS-acting Agents Revenue by Region (2018-2023)
6.2 APAC RAS-acting Agents Sales by Type
6.3 APAC RAS-acting Agents Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe RAS-acting Agents by Country
7.1.1 Europe RAS-acting Agents Sales by Country (2018-2023)
7.1.2 Europe RAS-acting Agents Revenue by Country (2018-2023)
7.2 Europe RAS-acting Agents Sales by Type
7.3 Europe RAS-acting Agents Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa RAS-acting Agents by Country
8.1.1 Middle East & Africa RAS-acting Agents Sales by Country (2018-2023)
8.1.2 Middle East & Africa RAS-acting Agents Revenue by Country (2018-2023)
8.2 Middle East & Africa RAS-acting Agents Sales by Type
8.3 Middle East & Africa RAS-acting Agents Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of RAS-acting Agents
10.3 Manufacturing Process Analysis of RAS-acting Agents
10.4 Industry Chain Structure of RAS-acting Agents
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 RAS-acting Agents Distributors
11.3 RAS-acting Agents Customer
12 World Forecast Review for RAS-acting Agents by Geographic Region
12.1 Global RAS-acting Agents Market Size Forecast by Region
12.1.1 Global RAS-acting Agents Forecast by Region (2024-2029)
12.1.2 Global RAS-acting Agents Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global RAS-acting Agents Forecast by Type
12.7 Global RAS-acting Agents Forecast by Application
13 Key Players Analysis
13.1 Novartis AG
13.1.1 Novartis AG Company Information
13.1.2 Novartis AG RAS-acting Agents Product Portfolios and Specifications
13.1.3 Novartis AG RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novartis AG Main Business Overview
13.1.5 Novartis AG Latest Developments
13.2 Pfizer, Inc.
13.2.1 Pfizer, Inc. Company Information
13.2.2 Pfizer, Inc. RAS-acting Agents Product Portfolios and Specifications
13.2.3 Pfizer, Inc. RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer, Inc. Main Business Overview
13.2.5 Pfizer, Inc. Latest Developments
13.3 AstraZeneca plc
13.3.1 AstraZeneca plc Company Information
13.3.2 AstraZeneca plc RAS-acting Agents Product Portfolios and Specifications
13.3.3 AstraZeneca plc RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 AstraZeneca plc Main Business Overview
13.3.5 AstraZeneca plc Latest Developments
13.4 Merck & Co., Inc.
13.4.1 Merck & Co., Inc. Company Information
13.4.2 Merck & Co., Inc. RAS-acting Agents Product Portfolios and Specifications
13.4.3 Merck & Co., Inc. RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Merck & Co., Inc. Main Business Overview
13.4.5 Merck & Co., Inc. Latest Developments
13.5 Sanofi S.A.
13.5.1 Sanofi S.A. Company Information
13.5.2 Sanofi S.A. RAS-acting Agents Product Portfolios and Specifications
13.5.3 Sanofi S.A. RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sanofi S.A. Main Business Overview
13.5.5 Sanofi S.A. Latest Developments
13.6 Bristol-Myers Squibb Company
13.6.1 Bristol-Myers Squibb Company Company Information
13.6.2 Bristol-Myers Squibb Company RAS-acting Agents Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb Company RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bristol-Myers Squibb Company Main Business Overview
13.6.5 Bristol-Myers Squibb Company Latest Developments
13.7 Daiichi Sankyo Company, Limited
13.7.1 Daiichi Sankyo Company, Limited Company Information
13.7.2 Daiichi Sankyo Company, Limited RAS-acting Agents Product Portfolios and Specifications
13.7.3 Daiichi Sankyo Company, Limited RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Daiichi Sankyo Company, Limited Main Business Overview
13.7.5 Daiichi Sankyo Company, Limited Latest Developments
13.8 Takeda Pharmaceutical Company Limited
13.8.1 Takeda Pharmaceutical Company Limited Company Information
13.8.2 Takeda Pharmaceutical Company Limited RAS-acting Agents Product Portfolios and Specifications
13.8.3 Takeda Pharmaceutical Company Limited RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.8.5 Takeda Pharmaceutical Company Limited Latest Developments
13.9 Boehringer Ingelheim GmbH
13.9.1 Boehringer Ingelheim GmbH Company Information
13.9.2 Boehringer Ingelheim GmbH RAS-acting Agents Product Portfolios and Specifications
13.9.3 Boehringer Ingelheim GmbH RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Boehringer Ingelheim GmbH Main Business Overview
13.9.5 Boehringer Ingelheim GmbH Latest Developments
13.10 Johnson & Johnson
13.10.1 Johnson & Johnson Company Information
13.10.2 Johnson & Johnson RAS-acting Agents Product Portfolios and Specifications
13.10.3 Johnson & Johnson RAS-acting Agents Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Johnson & Johnson Main Business Overview
13.10.5 Johnson & Johnson Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. RAS-acting Agents Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. RAS-acting Agents Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of ACE Inhibitors
Table 4. Major Players of Angiotensin II Receptor Blockers (ARBs)
Table 5. Major Players of Renin Inhibitors
Table 6. Major Players of Aldosterone Antagonists
Table 7. Major Players of Others (diuretics)
Table 8. Global RAS-acting Agents Sales by Type (2018-2023) & (K Units)
Table 9. Global RAS-acting Agents Sales Market Share by Type (2018-2023)
Table 10. Global RAS-acting Agents Revenue by Type (2018-2023) & ($ million)
Table 11. Global RAS-acting Agents Revenue Market Share by Type (2018-2023)
Table 12. Global RAS-acting Agents Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global RAS-acting Agents Sales by Application (2018-2023) & (K Units)
Table 14. Global RAS-acting Agents Sales Market Share by Application (2018-2023)
Table 15. Global RAS-acting Agents Revenue by Application (2018-2023)
Table 16. Global RAS-acting Agents Revenue Market Share by Application (2018-2023)
Table 17. Global RAS-acting Agents Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global RAS-acting Agents Sales by Company (2018-2023) & (K Units)
Table 19. Global RAS-acting Agents Sales Market Share by Company (2018-2023)
Table 20. Global RAS-acting Agents Revenue by Company (2018-2023) ($ Millions)
Table 21. Global RAS-acting Agents Revenue Market Share by Company (2018-2023)
Table 22. Global RAS-acting Agents Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers RAS-acting Agents Producing Area Distribution and Sales Area
Table 24. Players RAS-acting Agents Products Offered
Table 25. RAS-acting Agents Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global RAS-acting Agents Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global RAS-acting Agents Sales Market Share Geographic Region (2018-2023)
Table 30. Global RAS-acting Agents Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global RAS-acting Agents Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global RAS-acting Agents Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global RAS-acting Agents Sales Market Share by Country/Region (2018-2023)
Table 34. Global RAS-acting Agents Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global RAS-acting Agents Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas RAS-acting Agents Sales by Country (2018-2023) & (K Units)
Table 37. Americas RAS-acting Agents Sales Market Share by Country (2018-2023)
Table 38. Americas RAS-acting Agents Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas RAS-acting Agents Revenue Market Share by Country (2018-2023)
Table 40. Americas RAS-acting Agents Sales by Type (2018-2023) & (K Units)
Table 41. Americas RAS-acting Agents Sales by Application (2018-2023) & (K Units)
Table 42. APAC RAS-acting Agents Sales by Region (2018-2023) & (K Units)
Table 43. APAC RAS-acting Agents Sales Market Share by Region (2018-2023)
Table 44. APAC RAS-acting Agents Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC RAS-acting Agents Revenue Market Share by Region (2018-2023)
Table 46. APAC RAS-acting Agents Sales by Type (2018-2023) & (K Units)
Table 47. APAC RAS-acting Agents Sales by Application (2018-2023) & (K Units)
Table 48. Europe RAS-acting Agents Sales by Country (2018-2023) & (K Units)
Table 49. Europe RAS-acting Agents Sales Market Share by Country (2018-2023)
Table 50. Europe RAS-acting Agents Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe RAS-acting Agents Revenue Market Share by Country (2018-2023)
Table 52. Europe RAS-acting Agents Sales by Type (2018-2023) & (K Units)
Table 53. Europe RAS-acting Agents Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa RAS-acting Agents Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa RAS-acting Agents Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa RAS-acting Agents Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa RAS-acting Agents Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa RAS-acting Agents Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa RAS-acting Agents Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of RAS-acting Agents
Table 61. Key Market Challenges & Risks of RAS-acting Agents
Table 62. Key Industry Trends of RAS-acting Agents
Table 63. RAS-acting Agents Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. RAS-acting Agents Distributors List
Table 66. RAS-acting Agents Customer List
Table 67. Global RAS-acting Agents Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global RAS-acting Agents Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas RAS-acting Agents Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas RAS-acting Agents Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC RAS-acting Agents Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC RAS-acting Agents Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe RAS-acting Agents Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe RAS-acting Agents Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa RAS-acting Agents Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa RAS-acting Agents Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global RAS-acting Agents Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global RAS-acting Agents Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global RAS-acting Agents Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global RAS-acting Agents Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Novartis AG Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 82. Novartis AG RAS-acting Agents Product Portfolios and Specifications
Table 83. Novartis AG RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. Novartis AG Main Business
Table 85. Novartis AG Latest Developments
Table 86. Pfizer, Inc. Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 87. Pfizer, Inc. RAS-acting Agents Product Portfolios and Specifications
Table 88. Pfizer, Inc. RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. Pfizer, Inc. Main Business
Table 90. Pfizer, Inc. Latest Developments
Table 91. AstraZeneca plc Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 92. AstraZeneca plc RAS-acting Agents Product Portfolios and Specifications
Table 93. AstraZeneca plc RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. AstraZeneca plc Main Business
Table 95. AstraZeneca plc Latest Developments
Table 96. Merck & Co., Inc. Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 97. Merck & Co., Inc. RAS-acting Agents Product Portfolios and Specifications
Table 98. Merck & Co., Inc. RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. Merck & Co., Inc. Main Business
Table 100. Merck & Co., Inc. Latest Developments
Table 101. Sanofi S.A. Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 102. Sanofi S.A. RAS-acting Agents Product Portfolios and Specifications
Table 103. Sanofi S.A. RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. Sanofi S.A. Main Business
Table 105. Sanofi S.A. Latest Developments
Table 106. Bristol-Myers Squibb Company Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 107. Bristol-Myers Squibb Company RAS-acting Agents Product Portfolios and Specifications
Table 108. Bristol-Myers Squibb Company RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Bristol-Myers Squibb Company Main Business
Table 110. Bristol-Myers Squibb Company Latest Developments
Table 111. Daiichi Sankyo Company, Limited Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 112. Daiichi Sankyo Company, Limited RAS-acting Agents Product Portfolios and Specifications
Table 113. Daiichi Sankyo Company, Limited RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 114. Daiichi Sankyo Company, Limited Main Business
Table 115. Daiichi Sankyo Company, Limited Latest Developments
Table 116. Takeda Pharmaceutical Company Limited Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 117. Takeda Pharmaceutical Company Limited RAS-acting Agents Product Portfolios and Specifications
Table 118. Takeda Pharmaceutical Company Limited RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 119. Takeda Pharmaceutical Company Limited Main Business
Table 120. Takeda Pharmaceutical Company Limited Latest Developments
Table 121. Boehringer Ingelheim GmbH Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 122. Boehringer Ingelheim GmbH RAS-acting Agents Product Portfolios and Specifications
Table 123. Boehringer Ingelheim GmbH RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 124. Boehringer Ingelheim GmbH Main Business
Table 125. Boehringer Ingelheim GmbH Latest Developments
Table 126. Johnson & Johnson Basic Information, RAS-acting Agents Manufacturing Base, Sales Area and Its Competitors
Table 127. Johnson & Johnson RAS-acting Agents Product Portfolios and Specifications
Table 128. Johnson & Johnson RAS-acting Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 129. Johnson & Johnson Main Business
Table 130. Johnson & Johnson Latest Developments
List of Figures
Figure 1. Picture of RAS-acting Agents
Figure 2. RAS-acting Agents Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global RAS-acting Agents Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global RAS-acting Agents Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. RAS-acting Agents Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of ACE Inhibitors
Figure 10. Product Picture of Angiotensin II Receptor Blockers (ARBs)
Figure 11. Product Picture of Renin Inhibitors
Figure 12. Product Picture of Aldosterone Antagonists
Figure 13. Product Picture of Others (diuretics)
Figure 14. Global RAS-acting Agents Sales Market Share by Type in 2022
Figure 15. Global RAS-acting Agents Revenue Market Share by Type (2018-2023)
Figure 16. RAS-acting Agents Consumed in Hospital Pharmacies
Figure 17. Global RAS-acting Agents Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 18. RAS-acting Agents Consumed in Retail Pharmacies
Figure 19. Global RAS-acting Agents Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 20. RAS-acting Agents Consumed in Online Pharmacies
Figure 21. Global RAS-acting Agents Market: Online Pharmacies (2018-2023) & (K Units)
Figure 22. Global RAS-acting Agents Sales Market Share by Application (2022)
Figure 23. Global RAS-acting Agents Revenue Market Share by Application in 2022
Figure 24. RAS-acting Agents Sales Market by Company in 2022 (K Units)
Figure 25. Global RAS-acting Agents Sales Market Share by Company in 2022
Figure 26. RAS-acting Agents Revenue Market by Company in 2022 ($ Million)
Figure 27. Global RAS-acting Agents Revenue Market Share by Company in 2022
Figure 28. Global RAS-acting Agents Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global RAS-acting Agents Revenue Market Share by Geographic Region in 2022
Figure 30. Americas RAS-acting Agents Sales 2018-2023 (K Units)
Figure 31. Americas RAS-acting Agents Revenue 2018-2023 ($ Millions)
Figure 32. APAC RAS-acting Agents Sales 2018-2023 (K Units)
Figure 33. APAC RAS-acting Agents Revenue 2018-2023 ($ Millions)
Figure 34. Europe RAS-acting Agents Sales 2018-2023 (K Units)
Figure 35. Europe RAS-acting Agents Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa RAS-acting Agents Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa RAS-acting Agents Revenue 2018-2023 ($ Millions)
Figure 38. Americas RAS-acting Agents Sales Market Share by Country in 2022
Figure 39. Americas RAS-acting Agents Revenue Market Share by Country in 2022
Figure 40. Americas RAS-acting Agents Sales Market Share by Type (2018-2023)
Figure 41. Americas RAS-acting Agents Sales Market Share by Application (2018-2023)
Figure 42. United States RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC RAS-acting Agents Sales Market Share by Region in 2022
Figure 47. APAC RAS-acting Agents Revenue Market Share by Regions in 2022
Figure 48. APAC RAS-acting Agents Sales Market Share by Type (2018-2023)
Figure 49. APAC RAS-acting Agents Sales Market Share by Application (2018-2023)
Figure 50. China RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 54. India RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe RAS-acting Agents Sales Market Share by Country in 2022
Figure 58. Europe RAS-acting Agents Revenue Market Share by Country in 2022
Figure 59. Europe RAS-acting Agents Sales Market Share by Type (2018-2023)
Figure 60. Europe RAS-acting Agents Sales Market Share by Application (2018-2023)
Figure 61. Germany RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 62. France RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa RAS-acting Agents Sales Market Share by Country in 2022
Figure 67. Middle East & Africa RAS-acting Agents Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa RAS-acting Agents Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa RAS-acting Agents Sales Market Share by Application (2018-2023)
Figure 70. Egypt RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country RAS-acting Agents Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of RAS-acting Agents in 2022
Figure 76. Manufacturing Process Analysis of RAS-acting Agents
Figure 77. Industry Chain Structure of RAS-acting Agents
Figure 78. Channels of Distribution
Figure 79. Global RAS-acting Agents Sales Market Forecast by Region (2024-2029)
Figure 80. Global RAS-acting Agents Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global RAS-acting Agents Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global RAS-acting Agents Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global RAS-acting Agents Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global RAS-acting Agents Revenue Market Share Forecast by Application (2024-2029)

★調査レポート[世界のRAS作用剤市場予測 2023年-2029年] (コード：LP23DC00837)販売に関する免責事項を必ずご確認ください。

★調査レポート[世界のRAS作用剤市場予測 2023年-2029年]についてメールでお問い合わせ

カテゴリー：世界, 医療/バイオ, LP Information

世界のRAS作用剤市場予測 2023年-2029年

【英語タイトル】Global RAS-acting Agents Market Growth 2023-2029

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥541,680	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥812,520	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,083,360	見積依頼/購入/質問フォーム

❖ レポートの概要 ❖

❖ レポートの目次 ❖

★調査レポート[世界のRAS作用剤市場予測 2023年-2029年] (コード：LP23DC00837)販売に関する免責事項を必ずご確認ください。

★調査レポート[世界のRAS作用剤市場予測 2023年-2029年]についてメールでお問い合わせ

◆H&Iグローバルリサーチのお客様（例）◆

MarketReport.jp

世界のRAS作用剤市場予測 2023年-2029年

世界のRAS作用剤市場予測 2023年-2029年

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料 総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp